EGFR and non-small cell lung carcinoma: EGFR-TKIs treatment can also lead to a decrease in PD-1, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and T cell immunoglobulin and mucin domain-containing protein 3 expression in T cells in mouse models [98] in NSCLC patients who failed TKIs therapy followed by drug resistance.